Medication info

Atriple Plus Injection (Pre-filled) (Sodium Hyaluronate)

Prescription medicationInjection
Ingredient · strength
Sodium Hyaluronate›10mg / 1mL
Manufacturer / importer
Youyoung Pharmaceutical Co., Ltd.
Appearance
A colorless, transparent, viscous liquid contained in a glass or plastic vial with rubber stoppers on both ends (part of a pre-filled syringe system)
Packaging
2 milliliters / pre-filled syringe (2ml x 3 vials) (for domestic use), 2 milliliters / pre-filled syringe (2ml x 1 vial) (for export), 2 milliliters / pre-filled syringe (2ml x 3 vials) (for export), 2 milliliters / pre-filled syringe (2ml x 10 vials) (for export)
Approval status
Active

MFDS item code 200612721 · Notified 2006.12.20 · Insurance code 648201051

Summary

Main use
Treatment of periarthritis of the shoulder and knee osteoarthritis
Who receives it
Adults
Adult administration
Adults: Usually, administer 1 syringe once weekly for 3 consecutive weeks into the knee joint or shoulder joint (glenohumeral joint, subacromial bursa, or tendon sheath of the long head of the biceps), but adjust the number of administrations as appropriate according to symptoms. As this medicine is administered into a joint, it must be administered using strict aseptic technique.

Ingredients

Manufacturer
Youyoung Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of periarthritis of the shoulder and knee osteoarthritis

  • Knee osteoarthritis
  • adhesive capsulitis of the shoulder
View approved original text

This drug is used to treat knee osteoarthritis and adhesive capsulitis of the shoulder.

How it is given

Adult administration

Adults: Usually, administer 1 syringe once weekly for 3 consecutive weeks into the knee joint or shoulder joint (glenohumeral joint, subacromial bursa, or tendon sheath of the long head of the biceps), but adjust the number of administrations as appropriate according to symptoms. As this medicine is administered into a joint, it must be administered using strict aseptic technique.

Precautions

This drug should not be administered to patients who have previously experienced allergic reactions to any component of this product. Caution should be exercised when administering to patients who have had allergic reactions to other medications or who have liver dysfunction or a history of liver disease. Liver function tests may show abnormal results in patients with liver dysfunction. Additionally, since this drug is administered directly into the joint, it should be used cautiously if there is any skin condition or infection at the site of injection. Severe allergic reactions such as shock symptoms may occur when using this drug, so patients must be closely monitored. If any unusual symptoms occur, administration should be immediately stopped and appropriate treatment should be provided. Common side effects may include swelling of the face or around the eyes, skin rash, hives, and itching, so if these symptoms occur, discontinuation and treatment should be sought. Transient pain, swelling, redness, warmth, and severe pressure sensation may occur at the injection site in the joint, and systemic symptoms such as nausea, vomiting, and fever may also appear. For patients with severe inflammatory degenerative joint disease, it is advisable to reduce inflammation before administering this product. After administration, measures to stabilize the joint area are necessary. If the drug leaks outside the joint, pain may occur, so it must be injected accurately into the joint. Sterile conditions must be strictly maintained during injection, and if symptoms do not improve, administration should only be done up to three times and then stopped. If there is significant accumulation of joint fluid, it may need to be drained as needed. This drug should not be administered intravenously or for ophthalmological use, and appropriate sized needles should be used. Caution is also required as precipitation may occur when mixed with certain disinfectants. Pregnant women or those who may become pregnant should only use this drug cautiously if absolutely necessary, and breastfeeding women should avoid breastfeeding while receiving this treatment. Safety has not been established in children, so it should only be used cautiously when necessary.

Side effects

Shock symptoms, edema (facial, eyelid, etc.), facial flushing, rash, urticaria, itching, pain (mainly transient pain after administration), swelling, fluid retention, erythema, warmth, severe local pressure sensation, nausea, vomiting, fever

Not everyone experiences these, and they can vary from person to person.

Storage

This drug should be stored in a sealed container to prevent exposure to air, and it is recommended to keep it at room temperature, between 1 to 30 degrees Celsius, to maintain its efficacy.

Appearance and packaging

Appearance

A colorless, transparent, viscous liquid contained in a glass or plastic vial with rubber stoppers on both ends (part of a pre-filled syringe system)

Package unit

2 milliliters / pre-filled syringe (2ml x 3 vials) (for domestic use), 2 milliliters / pre-filled syringe (2ml x 1 vial) (for export), 2 milliliters / pre-filled syringe (2ml x 3 vials) (for export), 2 milliliters / pre-filled syringe (2ml x 10 vials) (for export)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.